Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfo...
/PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection...
prnewswire.com